Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioCardia ( (BCDA) ) has shared an announcement.
On October 2, 2025, BioCardia, Inc. announced it has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), ensuring its continued listing on the Nasdaq Stock Market. This achievement follows BioCardia’s efforts to strengthen its financial position by raising capital to support the development of its therapeutic candidates and advance its approved products.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is primarily impacted by its weak financial performance and challenging valuation. While there are positive developments in clinical trials and regulatory pathways, the financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., based in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company develops biotherapeutic platforms, including CardiAMP® and CardiALLO™ cell therapies, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms.
Average Trading Volume: 767,089
Technical Sentiment Signal: Sell
Current Market Cap: $14.11M
For a thorough assessment of BCDA stock, go to TipRanks’ Stock Analysis page.